Sorry to beat a dead horse, but gestalt, Saltz, an
Post# of 148164
I guess it is just life, but it does beg the question why would anyone be foolish enough to invest in the next OTC biotech, especially in its early stages? Take all the risk, get none of the benefits. What a deal.
I know, just let it go. Done with the OTC if this hits.